Back to search

Article

Cas9-AAV6 Gene Correction of Beta-Globin in Autologous HSCs Improves Sickle Cell Disease Erythropoiesis in Mice

2020-10-13

Abstract excerpt

CRISPR/Cas9-mediated beta-globin ( HBB ) gene correction of Sickle Cell Disease (SCD) patient-derived hematopoietic stem cells (HSCs) in combination with autologous transplantation represents a novel paradigm in gene therapy. Although several Cas9-based HBB -correction approaches have been proposed, functional correction of in vivo erythropoiesis has not been investigated. Here, we used a humanized globin-cluste...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ccb1000b-d73f-5876-8ccb-8d6f308bbfb5
DOI
10.1101/2020.10.13.338319
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cas9-AAV6 Gene Correction of Beta-Globin in Autologous HSCs Improves Sickle Cell Disease Erythropoiesis in MiceDOI 10.1101/2020.10.13.338319
Select a neighboring publication to make it the new centre.